



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX DETECTS SCRAPIE PRIONS IN BLOOD FROM ASYMPTOMATIC SHEEP

TORONTO, ON, April 29, 2008 – Amorfix Life Sciences Ltd. announced today the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human vCJD in the United Kingdom. Scrapie, a disease in sheep similar to mad cow disease, is endemic in almost all the flocks of the 1 billion sheep in the world. Europe and North America have had programs to eradicate scrapie for many years and still have scrapie-infected herds. There were 76 newly-infected flocks identified in the United States in 2007.

“Identification of scrapie sheep prior to symptoms is critical for an effective program to eradicate the disease,” said Dr. George Adams, Chief Executive Officer, Amorfix. “For the first time, we have been able to sort scrapie infected and unaffected sheep using a simple blood test.”

Scrapie-infected lambs as early as 17 months of age were detected by the Amorfix EP-TSE™ test. Sheep normally show symptoms of scrapie at 3 to 5 years of age. Detection of infected sheep 2 to 3 years prior to symptoms will allow effective removal of infected animals before they have the ability to infect other sheep in the flock. There are over 2,450 sheep ranchers in the United States who have joined the voluntary Scrapie Flock Certification Program which began in 1992 after attempts to eradicate scrapie starting in 1952 were unsuccessful. To date, 492 flocks have been certified as it requires 5 years of continuous monitoring and verification of absence of disease. Similar eradication programs are ongoing in Europe with significant subsidies by the European Commission (\$60M in 2007) to eradicate scrapie through genetic testing and culling of susceptible sheep.

Current post-mortem testing of scrapie costs \$30 dollars per test and is labour-intensive as it requires extensive brain tissue preparation. A simple blood test could be used for surveillance as well as eradication and would lead to the identification of animals earlier. There are 100 million sheep in Europe and 8 million sheep in North America. The testing of all sheep in these continents would eradicate scrapie once and for all. Australia and New Zealand have been scrapie free for decades and enjoy premium prices for their products and exclusive access to markets worldwide for live animals.

Amorfix is in discussions with potential partners to complete product development, regulatory approvals and commercialize the EP-TSE™ test. The company continues to validate its EP-CJD™ test through the UK process and participate in the development of a common technical specification for a CE mark.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---